Posted by Michael Wonder on 21 Feb 2019
Neurelis announces that Intravail licensee ARS Pharmaceuticals intranasal epinephrine program given fast track designation
20 February 2019 - ARS Pharmaceuticals announced that ARS-1, an intranasal epinephrine spray in development to treat severe allergic reactions, was granted fast track designation by the U.S. FDA.
Neurelis announced today that its Intravail licensing partner, ARS Pharmaceuticals, Inc., received Fast Track designation from the FDA for ARS-1, its novel intranasal epinephrine spray. ARS-1 is being investigated as a treatment for patients with severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.
